Skip to main content
. 2020 Feb 24;10:3245. doi: 10.1038/s41598-020-60195-z

Figure 5.

Figure 5

Innate CD8 T-cell frequency increases in CML patients under dasatinib treatment. PBMCs isolated from patients (n = 15) at CML diagnosis (Dg) or after 3 months of dasatinib (Dasa) treatment were analyzed by flow cytometry for panKIR/NKG2A+ Eomes+ innate CD8 T-cells (A). Eomes and CD49d MFI were analyzed in innate CD8 T-cells (B). Representative plots are shown. Statistical analysis: paired two-tailed Wilcoxon test.